Objective The relative risk of SARS–CoV‐2 infection and COVID‐19 disease severity among
people with rheumatic and musculoskeletal diseases (RMDs) compared to those without …

Objectives The impact of rheumatic diseases on COVID-19 infection remains poorly
investigated. Here we performed a systematic review and meta-analysis to evaluate the …

Objectives To determine factors associated with COVID-19-related death in people with
rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease …

Aims Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin
converting enzyme 2 (ACE2) enabling entrance of the virus into cells and causing the …

Purpose of Review A growing body of evidence suggests that obesity and increased visceral
adiposity are strongly and independently linked to adverse outcomes and death due to …

Objectives Acute respiratory distress syndrome and cytokine release syndrome are the
major complications of coronavirus disease 2019 (COVID-19) associated with increased …

Background At the end of 2021, the European Medicines Agency (EMA) expanded its
approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the …

Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 and its associated
pathology, COVID-19, have been of particular concerns these last months due to the …

Background SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) and neuropilin-
1 (NRP1) receptors for entry into cells, and the serine protease TMPRSS2 for S protein …

There is concern that people with rheumatic disease, often treated with immunosuppressive
or immunomodulatory medication, may be at an increased risk of poor outcomes of novel …